Next Article in Journal
Structural and Mechanistic Insights into Dual Cholinesterase Inhibition by Marine Phytohormones
Previous Article in Journal
Isolation of Phycobiliproteins from Thermosynechococcus PCC 6715 by Foam Fractionation in Batch and Continuous Modes
Previous Article in Special Issue
Anti-Inflammatory Secondary Metabolites from Penicillium sp. NX-S-6
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Marine Drugs
Volume 24
Issue 1
10.3390/md24010034
marinedrugs-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Chemical Investigation of the Global Regulator veA-Overexpressed Mutant of an Arctic Strain Aspergillus sydowii MNP-2

by
Qing Gong
1,2,
Wei Wang
1,2,
Yujie Zhao
1,2,
Xiaoying Wang
1,2,
Xuelian Bai
3,* and
Huawei Zhang
1,2,*
1
School of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, China
2
State Key Laboratory of Green Chemical Synthesis and Conversion, Zhejiang University of Technology, Hangzhou 310014, China
3
College of Life and Environmental Sciences, Hangzhou Normal University, Hangzhou 311121, China
*
Authors to whom correspondence should be addressed.
Mar. Drugs 2026, 24(1), 34; https://doi.org/10.3390/md24010034
Submission received: 9 December 2025 / Revised: 4 January 2026 / Accepted: 7 January 2026 / Published: 9 January 2026
(This article belongs to the Special Issue Structural Diversity in Marine Natural Products)
Browse Figures
Review Reports Versions Notes

Abstract

A growing body of evidence indicates that artificial manipulation of transcriptional regulation is a powerful approach to activate cryptic biosynthetic gene clusters (BGCs) of secondary metabolites (SMs) in fungi. In this study, one mutant strain MNP-2-OE::veA was constructed by overexpressing the global transcription regulator veA in an Arctic-derived strain Aspergillus sydowii MNP-2. Chemical investigation of the mutant OE::veA resulted in the isolation of one novel polyhydroxy anthraquinone (1) together with nine known metabolites (2–10), which were unambiguously characterized by various spectroscopic methods including 1D and 2D NMR and HR-ESI-MS as well as via comparison with literature data. Biosynthetically, compounds 1 and 10 as new arising chemicals were, respectively, formed by type II polyketide synthase (T2PK) and non-ribosomal peptide synthetase (NRPS), which were silent in the wild-type (WT) strain MNP-2. A bioassay showed that only compound 3 had weak inhibitory effect on human pathogen Candida albicans, with a MIC value of 64 ug/mL, and 4 displayed in vitro weak cytotoxic activity against HCT116 cells (IC50 = 44.47 μM). These results indicate that overexpression of veA effectively awakened the cryptic BGCs in fungal strains and enhanced their structural diversity in natural products.

1. Introduction

Marine-derived Aspergillus fungi produce a diverse array of structurally unique and biologically active secondary metabolites (SMs), representing a hotspot in current field of natural product research [1,2,3,4,5]. A. sydowii, a ubiquitous fungus widely distributed across various ecosystems, is renowned for its extraordinary environmental adaptability and impressive secondary metabolic potential [6]. Genome sequencing and bioinformatics analyses suggest that the number of SM biosynthetic gene clusters (BGCs) in A. sydowii strains far exceeds the chemical diversity of compounds produced by them [7,8]. Therefore, the vast majority of these BGCs remain transcriptionally silent, making the discovery of novel structures challenging. In the past two decades, multiple strategies, such as epigenetic regulation, promoter engineering, global regulation, and others, have been developed and employed to activate silenced BGCs, thereby activating fungal secondary metabolic capabilities and discovering diversified SMs [9,10,11]. Of these approaches, global regulatory factor modification is considered one of the most promising strategies due to its ability to simultaneously affect multiple BGCs and its straightforward operability. veA is one of the most prevalent global regulators within the Aspergillus genus, playing a pivotal role in modulating morphogenesis and secondary metabolism [12,13,14].
In our previous studies, we performed whole-genome analysis and metabolic profiling of an Arctic-derived fungus A. sydowii MNP-2 using the global natural product social molecular network (GNPS) approach, suggesting that this strain harbors biosynthetic potential to produce diverse SMs with complex structures and significant biological activities [15]. The chemical study of the wild-type (WT) strain MNP-2 had afforded 11 phenolic bisabolane sesquiterpenes (PBSs) from its rice and potato dextrose broth (PDB) fermentation extracts [16]. To awaken the latent BGCs in this strain to produce other bioactive SMs, one global regulator veA-overexpressed mutant OE::veA was successfully constructed and shown to make ten substances (1–10, Figure 1) including one novel polyhydroxy anthraquinone (1). This work highlights the construction of the veA-overexpressed mutant OE::veA and the isolation and elucidation of its derived SMs, as well as their biological properties.

2. Results and Discussion

2.1. Construction and Morphological Characterization of the Mutant Strain

Following genome sequencing and gene annotation analysis, the global regulator veA from A. sydowii MNP-2 (1755 bp in full length) was identified and selected as the target of this study. Specific primers were employed for the amplification of the veA gene, and the overexpression plasmid pOE::veA was subsequently generated (Figures S1 and S2). The overexpression mutant OE::veA was constructed using Agrobacterium tumefaciens-mediated transformation (ATMT) [17,18]. Furthermore, the Hyg resistance gene band could be specifically amplified from the transformed strains harboring the recombinant plasmid (Figure 2a). Real-time quantitative polymerase chain reaction (RT-qPCR) was performed to determine the expression level of veA in the OE::veA strain, with β-actin serving as the internal reference. Compared with the WT MNP-2, the veA gene expression level in the OE::veA strain was significantly increased by 346.94-fold (Table 1 and Figure 2b). Collectively, these findings confirmed the successful construction of the veA-overexpressing mutant OE::veA.
The WT strain A. sydowii MNP-2 was observed to produce significantly higher levels of red pigment, whereas the veA-overexpressing mutant OE::veA exhibited a marked reduction in pigment biosynthesis. Compared to the WT strain, OE::veA displayed three distinct colony phenotypic alterations: more pigmented spores, reduced surface wrinkling, and significantly larger colony diameters (Figure 3a). At the microscopic level, the WT strain MNP-2 formed dense, complex mycelial networks characterized by fewer conidia and minimal branching at hyphal tips. In contrast, OE::veA produced an increased number of conidia and developed longer, dendritic hyphal branches (Figure 3b).

2.2. LC-MS/MS Analysis of Mutant-Derived Crude Extracts

The liquid chromatography–mass spectrometry (LC-MS) data are shown in Figure 4. When cultured in modified Martin medium, the molecular weights of SMs from the WT strain MNP-2 were primarily concentrated with in the m/z 250–500 range, whereas those produced by the mutant strain OE::veA were concentrated in the m/z 200–400 range.

2.3. Isolation and Identification of OE::veA-Derived Secondary Metabolites

A total of ten compounds (1–10) were isolated from the modified Martin medium culture extract, comprising one novel compound (1) and nine known metabolites (2–10), including a rare diphenyl ether glycoside (3). Using HR-ESIMS and 1H NMR as well as comparison with literature data, these compounds were, respectively, identified as follows: 1,2,5,6-tetrahydroxy-3-(hydroxymethyl)-8-methoxy-9,10-anthraquinon (1) [19], diorcinol (2) [20], diorcinol-3-O-α-d-ribofuranoside (3) [21], acremolin B (4) [22], 10-hydroxysydonic acid (5) [23], cyclo (Leu-Pro) (6) [24], cyclo (L-Phe-4-OH-L-Pro) (7) [25], cyclo (L-(4-OH)-Pro-L-Leu) (8) [26], cyclo (L-Phenyl-L-tryptophyl) (9) [27], and WIN 64821 (10) [28].
Compound 1, obtained as a deep red powder that easily dissolves in DMSO-d6, is slightly soluble in methanol, and insoluble in chloroform. The molecular formula of 1 was established as C16H12O8 based on the sodium adduct molecular ion peak m/z 355.0433 [M+Na]+ obtained from HR-ESIMS, indicating a degree of unsaturation of 11. The 1H NMR spectrum (Figure S3) of 1 exhibits a methyl signal at δH 3.90 (3H, s), a methylene signal at δH 4.58 (2H, s), two aromatic protons at δH 6.99 (1H, s) and δH 7.88 (1H, s), and five active hydrogen signals at δH 13.97 (1H, brs), δH 13.87 (1H, brs), δH 11.28 (1H, brs), δH 10.51 (1H, brs), and δH 5.37 (1H, brs) (Table 2). Further analysis of its 13C NMR spectrum (Figure S4) indicates that compound 1 contains two ketone carbonyl signals at δC 185.4 and 187.2, along with twelve sp2-hybridized carbon signals at δC 157.1, 155.5, 149.4, 149.3, 147.6, 134.5, 121.9, 117.6, 115.6, 114.9, 108.7, and 106.3 ppm, which are similar to those of asperthecin, an anthraquinone pigment obtained from Aspergillus nidulans [19]. The key HMBC correlations from H-11 (δH 4.58) to C-2 (δC 149.4), C-3 (δC 134.5), and C-4 (δC 117.6), the oxygen methyl (δH 3.90) to C-8 (δC 157.1) and from H-7 (δH 6.99) to C-5 (δC 147.6), C-6 (δC 155.5), and C-8a (δC 108.7) support the assignment of the hydroxymethyl at the C3 position and the methoxy substitution at the C8 position (Figure 5). Therefore, compound 1 was unambiguously determined as 8-methoxyl-asperthecin.
Compound 2: Light yellow oily substance; soluble in methanol and chloroform. It is commonly distributed in soil fungi (serving as defensive metabolites against pathogens). Previous studies have documented its antimicrobial activity against Gram-positive bacteria Staphylococcus aureus, Bacillus subtilis, and the yeast Candida albicans [20].
Compound 3: Colorless oily substance; soluble in methanol and chloroform. Initially isolated from marine microbes, it exhibits cytotoxicity against multiple cancer cell lines, including human tissue cell lymphoma, human prostate cancer, and human colorectal adenocarcinoma cell lines [21].
Compound 4: White crystals; soluble in methanol and chloroform. It is primarily distributed in deep-sea-derived fungi [22].
Compound 5: White amorphous powder; soluble in methanol and chloroform. First isolated from marine fungi, it shows obvious inhibitory activities against pathogenic bacteria Escherichia coli, Edwardsiella tarda, Vibrio harveyi, and Vibrio parahaemolyticus [23].
Compounds 6–8: Colorless crystals; soluble in methanol and chloroform. Originally isolated from deep-sea sediments, prior bioinformatic analysis indicated that their biosynthesis is closely associated with four genes (jatA–D), which encode core non-ribosomal peptide synthetases and acetyltransferases [24,25,26].
Compound 9: White amorphous powder; soluble in methanol and chloroform. It was previously isolated from an unidentified Penicillium sp. [27].
Compound 10: White amorphous powder; soluble in methanol, slightly soluble in chloroform. It was initially derived from Aspergillus sp. It acts as a substance P (SP)-competitive antagonist binding to the human NK1 receptor, and also possesses significant NK2 receptor antagonistic activity [28].

2.4. Transcriptomic Analysis

To investigate the role of global regulatory factor veA in the biosynthesis of natural products in the mutant OE::veA, differential expression gene (DEG) analysis was carried out using transcriptomics technology. The results suggested that the mutant OE::veA had 608 upregulated genes and 635 downregulated genes compared with the WT strain MNP-2. Volcano plot analysis further validated the statistical significance of their gene expression differences (Figure 6a). Gene ontology (GO) enrichment analysis indicated that overexpression of the veA gene significantly affected metabolic process-related pathways in the strain, suggesting that this gene may be involved in regulating natural product biosynthesis through the modulation of metabolic networks (Figure 6b).
Among these greatly upregulated (p < 0.05) genes in the mutant OE::veA, nine SM biosynthesis-related genes were identified and shown to encode two polyketide synthases (PKSs), four non-ribosomal peptide synthetases (NRPSs), one terpene, one ribosomally synthesized and post-translationally modified peptide (RiPP), and one indole (Figure 7). Biosynthetically, compounds 1 and 10, as new arising SMs from the mutant OE::veA, were presumably formed by T2PK and NRPS, respectively. By Blastp-based homology alignment analysis, two upregulated PKS genes (g3871 and g9917) had a respective similarity of 56.6% and 46.43% with mdpG, which was essential for the biosynthesis of T2PK natural product xanthones [29]. The core gene (g5298), which exhibited upregulated expression in NRPS, shared 67% sequence similarity with dtpA, a key gene within the BGC responsible for the production of TDKPs [30]. Therefore, the overexpression of the veA gene activated the PKS and NRPS genes in the mutant OE::veA and resulted in the production of compounds 1 and 10.

2.5. Biological Activity of SMs

Antimicrobial assay revealed that compound 3 showed weak activity against C. albicans (MIC = 64 μg/mL). The cytotoxicity results for compounds (1–10) indicate that compound 4 with an IC50 value of 44.47 μM against HCT116 cells.

3. Materials and Methods

3.1. Fungal Material and Fermentation

The fungal strain A. sydowii MNP-2 was isolated from Arctic marine sediments. In this study, an overexpression strain of the global regulator veA, designated, was constructed from the WT MNP-2. For seed culture, OE::veA was inoculated into the modified Martin medium and incubated in the dark at 28 °C with shaking at 180 rpm for 15 days. For hyphal observation, 1 μL of a spore suspension (1 × 107 spores/mL) from both the WT and OE:: veA strains was aseptically placed into the gap between a PDA plate and a sterile coverslip. The plates were incubated at 28 °C in the dark for 2 days. The coverslips were then carefully removed with sterile forceps, placed onto glass slides, and stained with crystal violet. Hyphal growth and morphology were examined under an optical microscope.

3.2. Construction of Overexpression Mutant

Using the newly extracted genomic cDNA of A. sydowii MNP-2 as a template, primer pairs containing the target gene were designed for veA gene amplification. Following the PCR amplification of the target gene fragment, the veA gene was cloned downstream of the gpdA promoter in the fungal expression vector via restriction enzyme digestion and ligation, constructing the recombinant plasmid pOE::veA. The validated overexpression vector was introduced into Agrobacterium tumefaciens AGL-1 via freeze–thaw transformation. The successful transformant colonies were isolated and co-cultured with A. sydowii MNP-2. After the resistance screening, overexpressing positive transformants were obtained. RNA was extracted from positive transformants, reverse transcribed into cDNA, and validated via RT-qPCR. After ten generations of stable passage on antibiotic plates, RNA was extracted from overexpressing mutant strains and WT strains, was reverse transcribed into cDNA templates, and subjected to RT-qPCR to detect veA gene expression levels in the WT and mutant OE::veA strains. In the RT-qPCR analysis for assessing the expression level of the veA gene in the OE::veA mutant and WT MNP-2 strains, β-actin was utilized as the internal reference gene. Specifically, the ΔCt value for each sample was calculated as the difference between the cycle threshold (Ct) of the target gene (veA) and that of the internal reference gene (β-actin). Subsequently, the WT MNP-2 strain served as the control: its average ΔCt value was first determined, and the ΔΔCt value was then derived by subtracting this average ΔCt value from the ΔCt value of the OE::veA mutant. Finally, the relative overexpression level of veA in the OE::veA mutant was calculated using the 2−ΔΔCtmethod [31], which directly reflects the fold increase in veA expression in the mutant strain relative to the WT counterpart.
Using sterile pipettes, spore suspensions (spore concentration 1 × 107 spores/mL) of the WT and mutant strains were inoculated onto PDA plates. Plates were incubated at 28 °C for 8 days under dark conditions, with daily growth records taken for both strains. The positive mutant strain OE::veA maintained normal growth after the tenth generation, exhibiting significant phenotypic differences compared to the MNP-2 strain. The primers used in this study are detailed in Table S1.

3.3. General Experimental Procedures

1H NMR and 13C NMR spectra were recorded at 600 and 150 MHz, respectively, using Bruker Avance DRX600 instruments (Bruker, Fällande, Switzerland). ESIMS were obtainedwith an Agilent 6210 LC/TOF-MS spectrometer (Agilent Technologies, Santa Clara, CA, USA). Reverse phase HPLC wascarried out on an Essentia LC-16P apparatus (Essentia, San Diego, CA, USA) fitted with apreparative HPLC column (Phenomenex Gemini-NX C18 column 50 mm × 21.2 mm, 5 μm; Phenomenex, Inc., Torrance, CA, USA). It operated at a flow rate of 1.0 mL/min. All the chemicals used were of analytical grade.

3.4. Liquid Chromatography–Mass Spectrometry Analysis

A small amount of fermented crude extract was dried by blowing air, and then was adjusted to a concentration of 1 mg/mL. Centrifugation was performed at 12,000 rpm and 4 °C for 20 min, and the supernatant was collected into a sample vial. The instrumentation used was a SCIEX X500B quadrupole time-of-flight (QTOF) high-resolution mass spectrometer (HRMS) coupled with a SCIEX ExionLC ultra-high-performance liquid chromatograph (UPLC; SCIEX, Framingham, MA, USA). The liquid chromatography conditions were as follows: the analytical column was a Phenomenex Kinetex C18 column (100 Å, 150 × 2.1 mm, 5 μm; Phenomenex, Inc., Torrance, CA, USA), with gradient elution performed using a methanol/water (MeOH/H2O) mobile phase system ranging from 10% to 100% MeOH at a constant flow rate of 0.3 mL/min. Mass spectrometry (MS) conditions were configured as follows: electrospray ionization (ESI) was employed as the ion source, with full-scan mode performed for both positive and negative ion modes. The mass-to-charge ratio (m/z) range was set at 100–1500 for both full MS scan and MS/MS fragmentation analysis.

3.5. Extraction and Isolation

About 10.9 g of crude extract obtained from the fermentation broth of mutant strain OE::veA cultivated in modified Martin medium using ethyl acetate as extraction solvent was subjected to semi-preparative HPLC (Gemini NX-C18 110Å, 50 × 21.2 mm, 5 μm; Phenomenex, Inc., Torrance, CA, USA) using an acetonitrile–water gradient elution (30:70 to 100:0, v/v), yielding seven fractions (Fr.1–Fr.7). Fr.3 was further purified by gel column chromatography with a mobile phase of methanol/dichloromethane (1:1, v/v), affording four subfractions (Fr.3.1–Fr.3.4). Fr.3.2 was subsequently purified by semi-preparative HPLC (Gemini C18 110Å, 250 × 4.6 mm, 5 μm; Phenomenex, Inc., Torrance, CA, USA) using acetonitrile/water (15:85, v/v) as the mobile phase, yielding compounds 6 (5.4 mg, tR = 23.0 min), 7 (8.0 mg, tR = 11.2 min), and 8 (7.8 mg, tR = 17.9 min). Fr.4 was subjected to semi-preparative HPLC (Gemini NX-C18 110Å, 250 × 21.2 mm, 5 μm; Phenomenex, Inc., Torrance, CA, USA) using an acetonitrile–water gradient elution (20:80 to 100:0, v/v), yielding seven subfractions (Fr.4.1–Fr.4.7). A red solid precipitated upon the vacuum concentration of Fr.4.2, which was isolated as compound 1 (11.2 mg) after filtration. Fr.4.3 was further purified via semi-preparative HPLC (Gemini C18 110Å, 250 × 4.6 mm, 5 μm; Phenomenex, Inc., Torrance, CA, USA) using acetonitrile/0.1% aqueous formic acid (30:70, v/v) as the mobile phase, producing compound 5 (7.2 mg, tR = 9.7 min). Fr.4.4 was purified by semi-preparative HPLC (Gemini C18 110Å, 250 × 4.6 mm, 5 μm; Phenomenex, Inc., Torrance, CA, USA) to yield compounds 2 (7.9 mg, tR = 17.5 min, acetonitrile/water, 42:58, v/v) and 10 (19.1 mg, tR = 14.0 min, acetonitrile/0.1% aqueous formic acid, 45:55, v/v). Fr.4.5 was further subjected to purification using semi-preparative HPLC (Gemini C18 110Å, 250 × 4.6 mm, 5 μm; Phenomenex, Inc., Torrance, CA, USA) with a mobile phase of acetonitrile/water, yielding compounds 3 (3.1 mg, tR = 23.0 min, 28:82, v/v), 4 (5.8 mg, tR = 16.0 min, acetonitrile/water, 18:82, v/v), and 9 (7.4 mg, tR = 43.2 min, acetonitrile/water, 22:78, v/v).

3.6. Transcriptomic Analysis

For each sample, three sets of biological replicates were prepared. Library construction and Illumina sequencing were performed at Shanghai Personal Biotechnology Co. Ltd. (Hangzhou, China). The genes of differential expression were analyzed by DESeq (v1.38.3) with screen conditions as follows: expression difference multiple |log2FoldChange| > 1, significant p-value < 0.05. TopGO (v2.50.0) was used to perform GO enrichment analysis on the differentially expressed genes (all DEGs/up DEGs/down DEGs), to calculate the p-value using the hypergeometric distribution method (the standard of significant enrichment is p-value < 0.05), and to identify the GO terms with significantly enriched differential genes to determine the main biological functions performed by these differential genes. Sequence similarity was analyzed using the Blastp algorithm against the NCBI Non-Redundant Protein Database with an E-value cutoff set at 1 × 10−5.

3.7. Bioactivity Assay

According to the gradient dilution method [32], the antimicrobial activity of compounds 1–10 was tested against three indicator strains, including Staphylococcus aureus (S. aureus ATCC 25923), Escherichia coli (E. coli ATCC 25922), and Candida albicans (C. albicans ATCC 10231). Three pathogenic strains were obtained from Nanjing Medical University (Nanjing, China). A crude extract solution at a concentration of 10 mg/mL was prepared using DMSO. Ampicillin sodium served as the positive control for E. coli ATCC 25922 and S. aureus ATCC 25923, while amphotericin B was used as the positive control for C. albicans ATCC 10231. DMSO was used as the negative control.
The human breast cancer cell line MCF-7, the human hepatocellular carcinoma cell line HepG2, and the human colorectal cancer cell line HCT116 were purchased from the China Center for Type Culture Collection (CCTCC, Wuhan, China). The cytotoxicity of all chemicals 1–10 against MCF-7, HepG2, and HCT116 tumor cells was evaluated using the CCK-8 assay [33]. MCF-7 and HepG2 cells were cultured in DMEM medium, while HCT116 cells were maintained in RPMI 1640 medium (supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin). Cells were seeded into 96-well plates at a density of 5 × 103 cells/well (100 μL/well) and incubated at 37 °C with 5% CO2 for 24 h. Different concentrations of compounds 1–10 were then added, followed by a further incubation for 48 h. After the 48 h incubation, a medium containing 10% CCK-8 was added to each well, and the plates were incubated for an additional 40 min. The optical density (OD) values were measured at a wavelength of 450 nm using a microplate reader.

4. Conclusions

One veA-overexpressing mutant MNP-2-OE::veA was successfully constructed and shown to make one novel polyhydroxy anthraquinone (1) together with nine known metabolites (2–10), which compounds 1 and 10, respectively, biosynthesized by T2PK and NRPS, were newly emerging substances. These results demonstrated the crucial role of veA as a global transcription regulatory factor in activating silent BGCs in fungi, providing experimental evidence and theoretical support for enhancing chemical diversity through target gene regulation. In future, other transcription regulatory factors (such as LaeA and VelB) in the genome of WT strain MNP-2 will be further overexpressed or knocked out for discovery of novel SMs with therapeutic potential.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/md24010034/s1. Figure S1: Plasmid map of pOE::veA. Figure S2: The sequencing results of pOE::veA. Figures S3–S10: 1D, 2D NMR, and HRESIMS spectra of 1,2,5,6-tetrahydroxy-3-(hydroxymethyl)-8-methoxy-9,10-anthraquinon (1). Figures S11 and S12: 1D NMR spectra and HRESIMS spectra of diorcinol (2). Figures S13 and S14: 1D NMR spectra and HRESIMS spectra of diorcinol-3-O-α-d-ribofuranoside (3). Figures S15 and S16: 1D NMR spectra and HRESIMS spectra of acremolin B (4). Figures S17 and S18: 1D NMR spectra and HRESIMS spectra of 10-hydroxysydonic acid (5). Figures S19 and S20: 1D NMR spectra and HRESIMS spectra of cyclo (Leu-Pro) (6). Figures S21 and S22: 1D NMR spectra and HRESIMS spectra of cyclo (L-Phe-4-OH-L-Pro) (7). Figures S23 and S24: 1D NMR spectra and HRESIMS spectra of cyclo (L-(4-OH)-Pro-L-Leu) (8). Figures S25 and S26: 1D NMR spectra and HRESIMS spectra of cyclo (L-Phenyl-L-tryptophyl) (9). Figures S27–S29: 1D NMR spectra and HRESIMS spectra of WIN 64821 (10). Table S1: List of all used primers and their sequence. Table S2: The NMR spectroscopic data for diorcinol (2). Table S3: The NMR spectroscopic data for diorcinol-3-O-α-d-ribofuranoside (3). Table S4: The NMR spectroscopic data for acremolin B (4). Table S5: The NMR spectroscopic data for 10-hydroxysydonic acid (5). Table S6: The NMR spectroscopic data for cyclo (Leu-Pro) (6). Table S7: The NMR spectroscopic data for cyclo (L-Phe-4-OH-L-Pro) (7). Table S8: The NMR spectroscopic data for cyclo (L-(4-OH)-Pro-L-Leu) (8). Table S9: The NMR spectroscopic data for cyclo (L-Phenyl-L-tryptophyl) (9). Table S10: The NMR spectroscopic data for WIN 64821 (10).

Author Contributions

Conceptualization, Q.G. and Y.Z.; methodology, Y.Z. and X.W.; software, X.W.; validation, W.W. and Q.G.; formal analysis, Q.G. and W.W.; investigation, Y.Z. and Q.G.; data curation, Q.G. and W.W.; writing—original draft preparation, Q.G. and Y.Z.; writing—review and editing, Q.G. and H.Z.; visualization, Y.Z. and Q.G.; supervision and project administration, H.Z. and X.B.; and funding acquisition, H.Z. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Key Research and Development Program of China (2022YFC2804203).

Institutional Review Board Statement

Not applicable.

Data Availability Statement

The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author(s).

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
RT-qPCRreal-time quantitative polymerase chain reaction
T2PKtype II polyketide
GNPSglobal natural product social molecular network
NRPSNon-ribosomal peptide synthetase
PBSsphenolic bisabolane sesquiterpenes
BGCsbiosynthetic gene clusters
PDApotato dextrose agar medium
PDBpotato dextrose broth medium
MICminimum inhibitory concentration
DEGdifferential expression gene
SMssecondary metabolites
GOgene ontology
ODoptical density

References

  1. Song, Z.; Gao, J.; Hu, J.; He, H.; Huang, P.; Zhang, L.; Song, F. One new xanthenone from the marine-derived fungus Aspergillus versicolor MF160003. Nat. Prod. Res. 2020, 34, 2907–2912. [Google Scholar] [CrossRef]
  2. You, M.; Liao, L.; Hong, S.; Park, W.; Kwon, D.; Lee, J.; Noh, M.; Oh, D.; Oh, K.; Shin, J. Lumazine peptides from the marine-derived fungus Aspergillus terreus. Mar. Drugs 2015, 13, 1290–1303. [Google Scholar] [CrossRef] [PubMed]
  3. Hwang, J.; Lee, J.; Park, S.; Lee, J.; Oh, D.; Oh, K.; Shin, J. New peptides from the marine-derived fungi Aspergillus allahabadii and Aspergillus ochraceopetaliformis. Mar. Drugs 2019, 17, 488. [Google Scholar] [CrossRef] [PubMed]
  4. Han, Y.; Zhang, Q.; Xu, W.; Hai, Y.; Chao, R.; Wang, C.; Hou, X.; Wei, M.; Gu, Y.; Wang, C.; et al. Targeted isolation of antitubercular cycloheptapeptides and an unusual pyrroloindoline-containing new analog, asperpyrroindotide A, using LC-MS/MS-based molecular networking. Mar. Life Sci. Technol. 2023, 5, 85–93. [Google Scholar] [CrossRef]
  5. Andersen, M.; Nielsen, J.; Klitgaard, A.; Petersen, L.; Zachariasen, M.; Hansen, T.; Blicher, L.; Gotfredsen, C.; Larsen, T.; Nielsen, K.; et al. Accurate prediction of secondary metabolite gene clusters in filamentous fungi. Proc. Natl. Acad. Sci. USA 2013, 110, E99–E107. [Google Scholar] [CrossRef]
  6. Paulus, C.; Rebets, Y.; Tokovenko, B.; Nadmid, S.; Terekhova, L.P.; Myronovskyi, M.; Zotchev, S.B.; Rückert, C.; Braig, S.; Zahler, S.; et al. New natural products identified by combined genomics-metabolomics profiling of marine Streptomyces sp. MP131-18. Sci. Rep. 2017, 7, 42382. [Google Scholar] [CrossRef] [PubMed]
  7. Bergmann, S.; Schümann, J.; Scherlach, K.; Lange, C.; Brakhage, A.; Hertweck, C. Genomics-driven discovery of PKS-NRPS hybrid metabolites from Aspergillus nidulans. Nat. Chem. Biol. 2007, 3, 213–217. [Google Scholar] [CrossRef] [PubMed]
  8. Hou, X.; Liu, L.; Xu, D.; Lai, D.; Zhou, L. Involvement of LaeA and Velvet proteins in regulating the production of mycotoxins and other fungal secondary metabolites. J. Fungi 2024, 10, 561. [Google Scholar] [CrossRef]
  9. Zhang, Y.; Yu, W.; Lu, Y.; Wu, Y.; Ouyang, Z.; Tu, Y.; He, B. Epigenetic regulation of fungal secondary metabolism. J. Fungi 2024, 10, 648. [Google Scholar] [CrossRef]
  10. Liu, Y.; Tang, Y.; Fu, Z.; Zhu, W.; Wang, H.; Zhang, H. BGC heteroexpression strategy for production of novel microbial secondary metabolites. Metab. Eng. 2025, 91, 1–29. [Google Scholar] [CrossRef]
  11. Zhao, Y.; Gong, Q.; Zhang, H. Engineering of global transcriptional regulators (GTRs) in Aspergillus for natural product discovery. J. Fungi 2025, 11, 449. [Google Scholar] [CrossRef]
  12. Bok, J.; Keller, N. LaeA, a regulator of secondary metabolism in Aspergillus spp. Eukaryot. Cell 2004, 3, 527–535. [Google Scholar]
  13. Kale, S.; Milde, L.; Trpp, M.; Frisvad, J.; Keller, N.; Bok, J. Requirement of LaeA for secondary metabolism and sclerotial production in Aspergillus flavus. Fungal Genet. Biol. 2008, 45, 1422–1429. [Google Scholar] [CrossRef]
  14. Amaike, S.; Keller, N. Distinct roles for veA and LaeA in development and pathogenesis of Aspergillus flavus. Eukaryot. Cell 2009, 8, 1051–1060. [Google Scholar] [CrossRef] [PubMed]
  15. Fu, Z.; Gong, X.; Hu, Z.; Wei, B.; Zhang, H. Unveiling biosynthetic potential of an Arctic Marine-derived strain Aspergillus Sydowii MNP-2. BMC Genom. 2024, 25, 603. [Google Scholar] [CrossRef]
  16. Fu, Z.; Gong, X.; Hu, Z.; Zhao, Y.; Zhang, H. Phenolic bisabolane sesquiterpene derivatives from an Arctic Marine-derived Fungus Aspergillus sydowii MNP-2. Nat. Prod. J. 2024, 14, 10–15. [Google Scholar] [CrossRef]
  17. Chen, Z.; Debernardi, J.M.; Dubcovsky, J.; Gallavotti, A. Recent advances in crop transformation technologies. Nat. Plants 2022, 8, 1343–1351. [Google Scholar] [CrossRef]
  18. Dong, Y.H.; Wang, S.T. Agrobacterium tumefaciens-mediated transformation method for Fusarium oxysporum. Methods Mol. Biol. 2022, 2391, 63–73. [Google Scholar] [PubMed]
  19. Szewczyk, E.; Chiang, Y.M.; Oakley, C.E.; Davidson, A.D.; Wang, C.C.; Oakley, B.R. Identification and characterization of the asperthecin gene cluster of Aspergillus nidulans. Appl. Environ. Microbiol. 2008, 74, 7607–7612. [Google Scholar] [CrossRef]
  20. Yurchenko, A.N.; Smetanina, O.F.; Kalinovsky, A.I.; Pivkin, M.V.; Dmitrenok, P.S.; Kuznetsova, T.A. A new meroterpenoid from the marine fungus Aspergillus versicolor (Vuill.) Tirab. Russ. Chem. Bull. 2010, 59, 852–856. [Google Scholar] [CrossRef]
  21. Wang, Y.N.; Mou, Y.H.; Dong, Y.; Wu, Y.; Liu, B.Y.; Bai, J.; Yan, D.J.; Zhang, L.; Feng, D.Q.; Pei, Y.H.; et al. Diphenyl ethers from a marine-derived Aspergillus sydowii. Mar. Drugs 2018, 16, 451. [Google Scholar] [CrossRef]
  22. Tian, Y.; Qin, X.; Lin, X.; Kaliyaperumal, K.; Zhou, X.; Liu, J.; Ju, Z.; Tu, Z.; Liu, Y. Sydoxanthone C and acremolin B produced by deep-sea-derived fungus Aspergillus sp. SCSIO Ind09F01. J. Antibiot. 2015, 68, 703–706. [Google Scholar] [CrossRef]
  23. Li, X.D.; Li, X.M.; Yin, X.L.; Li, X.; Wang, B.G. Antimicrobial Sesquiterpenoid Derivatives and Monoterpenoids from the Deep-Sea Sediment-Derived Fungus Aspergillus versicolor SD-330. Mar. Drugs 2019, 17, 563. [Google Scholar] [CrossRef]
  24. Kim, J.; Hwang, S.J.; Lee, G.S.; Lee, J.R.; An, H.I.; Im, H.S.; Kim, M.; Lee, S.S.; Lee, H.J.; Kim, C.S. Collagenase and Tyrosinase Inhibitory Compounds from Fish Gut Bacteria Ruegeria atlantica and Pseudoalteromonas neustonica. ACS Omega 2024, 9, 34259–34267. [Google Scholar] [CrossRef] [PubMed]
  25. Lv, J.; Zhou, H.; Dong, L.; Wang, H.; Yang, L.; Yu, H.; Luo, B. Three new furanones from endophytic fungus Hypoxylon vinosopulvinatum DYR-1-7 from Cinnamomum cassia with their antifungal activity. Nat. Prod. Res. 2023, 38, 3165–3172. [Google Scholar] [CrossRef]
  26. Ding, W.; Li, Y.; Tian, X.; Xiao, Z.; Li, R.; Zhang, S.; Yin, H. Investigation on Metabolites in Structure and Biosynthesis from the Deep-Sea Sediment-Derived Actinomycete Janibacter sp. SCSIO 52865. Molecules 2023, 28, 2133. [Google Scholar] [CrossRef] [PubMed]
  27. Kimura, Y.; Tani, K.; Kojima, A.; Sotoma, G.; Okada, K.; Shimada, A. Cyclo-(l-tryptophyl-l-phenylalanyl), a plant growth regulator produced by the fungus Penicillium sp. Phytochemistry 1996, 41, 665–669. [Google Scholar] [CrossRef]
  28. Sedlock, D.M.; Barrow, C.J.; Brownell, J.E.; Hong, A.; Gillum, A.M.; Houck, D.R. WIN-64821, a novel neurokinin antagonist produced by an Aspergillus sp. II. Biological activity. J. Antibiot. 1994, 47, 391–398. [Google Scholar] [CrossRef]
  29. Sanchez, J.F.; Entwistle, R.; Hung, J.H.; Yaegashi, J.; Jain, S.; Chiang, Y.M.; Wang, C.C.; Oakley, B.R. Genome-based deletion analysis reveals the prenyl xanthone biosynthesis pathway in Aspergillus nidulans. J. Am. Chem. Soc. 2011, 133, 4010–4017. [Google Scholar] [CrossRef]
  30. Saruwatari, T.; Yagishita, F.; Mino, T.; Noguchi, H.; Hotta, K.; Watanabe, K. Cytochrome P450 as dimerization catalyst in diketopiperazine alkaloid biosynthesis. Chembiochem 2014, 15, 656–659. [Google Scholar] [CrossRef]
  31. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25, 402–408. [Google Scholar] [CrossRef] [PubMed]
  32. Balouiri, M.; Sadiki, M.; Ibnsouda, S.K. Methods for in vitro evaluating antimicrobial activity: A review. J. Pharm. Anal. 2016, 6, 71–79. [Google Scholar] [CrossRef] [PubMed]
  33. Lan, W.; Cai, J.; Yan, L.; Wu, X.; Zhang, L.; Chen, C.; Liu, Z.; Zhou, X.; Tang, L. Discovery of a hepatoprotective trinor-sesterterpenoid from the marine fungus Talaromyces sp. against hepatic ischemia-reperfusion Injury. Mar. Drugs 2025, 23, 329. [Google Scholar] [CrossRef] [PubMed]
Marinedrugs 24 00034 g001
Figure 1. Chemical structures of compounds (1–10) from the mutant OE::veA.
Figure 1. Chemical structures of compounds (1–10) from the mutant OE::veA.
Marinedrugs 24 00034 g001
Marinedrugs 24 00034 g002
Figure 2. Verification of veA-overexpressing mutant. (a) Amplification results of the anti-hygromycin fragment of veA-overexpressed transformants. Lane 1 and 2: OE::veA. (b) The relative expression level of the veA gene was verified by RT-qPCR.
Figure 2. Verification of veA-overexpressing mutant. (a) Amplification results of the anti-hygromycin fragment of veA-overexpressed transformants. Lane 1 and 2: OE::veA. (b) The relative expression level of the veA gene was verified by RT-qPCR.
Marinedrugs 24 00034 g002
Marinedrugs 24 00034 g003
Figure 3. Colony and spore morphology of strains MNP-2 (a) and OE::veA (b) on PDA.
Figure 3. Colony and spore morphology of strains MNP-2 (a) and OE::veA (b) on PDA.
Marinedrugs 24 00034 g003
Marinedrugs 24 00034 g004
Figure 4. LC-MS/MS analysis of crude extracts of strains MNP-2 (yellow) and OE::VeA (black). (a): Total ion chromatogram. (b): Three-dimensional visualization spectra.
Figure 4. LC-MS/MS analysis of crude extracts of strains MNP-2 (yellow) and OE::VeA (black). (a): Total ion chromatogram. (b): Three-dimensional visualization spectra.
Marinedrugs 24 00034 g004
Marinedrugs 24 00034 g005
Figure 5. The key HMBC correlation of compound 1.
Figure 5. The key HMBC correlation of compound 1.
Marinedrugs 24 00034 g005
Marinedrugs 24 00034 g006
Figure 6. Differential gene expression between the wild type and OE::veA.((a) the volcano plots of DEGs; (b) gene ontology enrichment analysis column chart of DEGs).
Figure 6. Differential gene expression between the wild type and OE::veA.((a) the volcano plots of DEGs; (b) gene ontology enrichment analysis column chart of DEGs).
Marinedrugs 24 00034 g006
Marinedrugs 24 00034 g007
Figure 7. OE::veA significantly upregulates core biosynthetic genes.
Figure 7. OE::veA significantly upregulates core biosynthetic genes.
Marinedrugs 24 00034 g007
Table 1. The real-time fluorescent quantitative PCR analysis results of veA gene.
Table 1. The real-time fluorescent quantitative PCR analysis results of veA gene.
NameSample CT MediumControlControl CT MediumΔCtΔΔCt
MNP-229.6012β-actin21.96997.63/
OE::veA22.5559β-actin23.3631−0.81−8.44
Table 2. 1H-NMR (600 MHz) and 13C-NMR (150 MHz) spectral data of compound 1 (δ in ppm, J in Hz).
Table 2. 1H-NMR (600 MHz) and 13C-NMR (150 MHz) spectral data of compound 1 (δ in ppm, J in Hz).
PositionδH (J in Hz)δCPositionδH (J in Hz)δC
1-149.31a-115.6
2-149.44a-114.9
3-134.58a-108.7
47.88 (1H, s)117.610a-121.9
5-147.68-OCH33.90 (3H, s)56.1
6-155.51-OH13.97 (1H, brs)-
76.99 (1H, s)106.32-OH11.28 (1H, brs)-
8-157.15-OH13.87 (1H, brs)-
9-185.46-OH10.51 (1H, brs)-
10-187.211-OH5.37 (1H, brs)-
114.58 (2H, s)57.64a-114.9
Recorded in DMSO-d6.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Gong, Q.; Wang, W.; Zhao, Y.; Wang, X.; Bai, X.; Zhang, H. Chemical Investigation of the Global Regulator veA-Overexpressed Mutant of an Arctic Strain Aspergillus sydowii MNP-2. Mar. Drugs 2026, 24, 34. https://doi.org/10.3390/md24010034

AMA Style

Gong Q, Wang W, Zhao Y, Wang X, Bai X, Zhang H. Chemical Investigation of the Global Regulator veA-Overexpressed Mutant of an Arctic Strain Aspergillus sydowii MNP-2. Marine Drugs. 2026; 24(1):34. https://doi.org/10.3390/md24010034

Chicago/Turabian Style

Gong, Qing, Wei Wang, Yujie Zhao, Xiaoying Wang, Xuelian Bai, and Huawei Zhang. 2026. "Chemical Investigation of the Global Regulator veA-Overexpressed Mutant of an Arctic Strain Aspergillus sydowii MNP-2" Marine Drugs 24, no. 1: 34. https://doi.org/10.3390/md24010034

APA Style

Gong, Q., Wang, W., Zhao, Y., Wang, X., Bai, X., & Zhang, H. (2026). Chemical Investigation of the Global Regulator veA-Overexpressed Mutant of an Arctic Strain Aspergillus sydowii MNP-2. Marine Drugs, 24(1), 34. https://doi.org/10.3390/md24010034

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop